Plant Name: Myristica fragrans
Taxonomic Information:
Plant ID: NPO5241
Plant Latin Name: Myristica fragrans
Taxonomy Genus: Myristica
Taxonomy Family: Myristicaceae
Plant External Links:
NCBI TaxonomyDB:
51089
Plant-of-the-World-Online:
586076-1
Used in Medicines:
Country/Region:
Brazil; Afghanistan; Yemen; Mexico; Lebanon; Indonesia; India; United States; Malaysia; Jordan; Germany; China; Sri Lanka; Thailand; IraqTraditional Medicine System:
Sowa-Rigpa; Indian Folk; Unani; Siddha; Ayurveda; TCM; HomeopathyGeographical Distribution:
Brazil; Afghanistan; Yemen; United States; Bangladesh; Mexico; Lebanon; Philippines; Indonesia; India; Jordan; Malaysia; Germany; Thailand; Sri Lanka; China; Taiwan; Iraq; Mauritius
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; ADRB3; ADRB1; ADRB2; HTR2B; HTR2A; HTR2C; | |
| TSHR; NPSR1; | |
| TDP1; RECQL; ALOX12; HSD17B2; HSD17B10; NOX4; POLB; | |
| CDC25B; | |
| MET; AXL; FLT3; CDK1; PIM1; KDR; IGF1R; AURKB; | |
| CA2; CA12; CA14; CA7; CA4; | |
| PPARA; | |
| RORC; | |
| NR1H4; | |
| TYR; | |
| MMP9; MMP1; MMP2; | |
| AHR; NFKB1; | |
| SLC6A4; | |
| LMNA; FABP5; FABP4; MAPT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| SLC superfamily of solute carriers | SLC6A4 | Serotonin transporter | P31645 | CHEMBL228 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADRB3 | Beta-3 adrenergic receptor | P13945 | CHEMBL246 |
| Small molecule receptor (family A GPCR) | ADRB1 | Beta-1 adrenergic receptor | P08588 | CHEMBL213 |
| Small molecule receptor (family A GPCR) | ADRB2 | Beta-2 adrenergic receptor | P07550 | CHEMBL210 |
| Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.020E-10 | 5.298E-07 | CA12, CA14, CA2, CA4, CA7 |
| MF | Unclassified; | GO:0004872; receptor activity | 8.704E-09 | 9.476E-06 | ADORA3, ADRB1, ADRB2, ADRB3, AHR, AXL, FLT3, HTR2A, HTR2B, HTR2C, IGF1R, KDR, MET, NPSR1, NR1H4, PPARA, RORC, TSHR |
| BP | GO:0065007; biological regulation | GO:0007190; activation of adenylate cyclase activity | 2.817E-08 | 1.979E-05 | ADORA3, ADRB1, ADRB2, ADRB3, TSHR |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.930E-08 | 3.509E-05 | CA12, CA14, CA2, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0010513; positive regulation of phosphatidylinositol biosynthetic process | 1.346E-07 | 6.104E-05 | HTR2A, HTR2B, HTR2C |
| MF | GO:0005488; binding | GO:0051380; norepinephrine binding | 1.346E-07 | 6.104E-05 | ADRB1, ADRB2, ADRB3 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 2.118E-07 | 8.701E-05 | ADRB1, ADRB2, ADRB3, MMP1, MMP2, MMP9 |
| BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 5.365E-07 | 1.718E-04 | ADRB1, ADRB2, ADRB3, HTR2A, HTR2B, SLC6A4 |
| BP | GO:0009987; cellular process | GO:0050873; brown fat cell differentiation | 6.034E-07 | 1.825E-04 | ADRB1, ADRB2, ADRB3, FABP4 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 6.624E-07 | 1.946E-04 | CA2, CA7, HTR2A, HTR2B, HTR2C, KDR, NPSR1 |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 6.702E-07 | 1.946E-04 | ALOX12, AURKB, AXL, CDK1, HTR2B, IGF1R, KDR, LMNA, MMP9, NFKB1, NR1H4, PIM1 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 6.614E-07 | 1.946E-04 | ADORA3, ADRB1, ADRB2, ADRB3, AXL, FLT3, HTR2A, HTR2B, HTR2C, IGF1R, KDR, MET, NPSR1, SLC6A4, TSHR |
| BP | GO:0032501; multicellular organismal process | GO:0031649; heat generation | 7.497E-07 | 2.120E-04 | ADRB1, ADRB2, ADRB3 |
| MF | GO:0005488; binding | GO:0051379; epinephrine binding | 7.497E-07 | 2.120E-04 | ADRB1, ADRB2, ADRB3 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 9.641E-07 | 2.441E-04 | ALOX12, CDC25B, CDK1, FLT3, HTR2A, HTR2B, IGF1R, KDR, MMP2, MMP9, PIM1, TSHR |
| BP | GO:0032502; developmental process | GO:0007568; aging | 1.337E-06 | 3.094E-04 | ADRB3, AURKB, CDK1, CYP1A1, HTR2A, NOX4, POLB |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.601E-06 | 3.451E-04 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.711E-06 | 3.583E-04 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 2.197E-06 | 4.350E-04 | HTR2A, HTR2B, HTR2C |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.260E-06 | 7.542E-04 | CYP1A1, CYP1A2, CYP1B1, NOX4 |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 4.459E-06 | 7.831E-04 | ADRB2, IGF1R, MMP2, NFKB1, NOX4, NR1H4, SLC6A4, TSHR |
| BP | GO:0009987; cellular process | GO:0007208; phospholipase C-activating serotonin receptor signaling pathway | 5.795E-06 | 9.706E-04 | HTR2A, HTR2C |
| MF | GO:0005488; binding | GO:0071886; 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding | 5.795E-06 | 9.706E-04 | HTR2A, HTR2C |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 6.015E-06 | 9.923E-04 | AHR, NR1H4, PPARA, RORC |
| BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 1.495E-05 | 2.128E-03 | ADRB1, ADRB2, ADRB3 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.736E-05 | 2.415E-03 | CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.741E-05 | 2.415E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0044877; macromolecular complex binding | 1.927E-05 | 2.639E-03 | ADRB2, FLT3, HTR2A, IGF1R, KDR, MAPT, MMP9, PIM1, PPARA, SLC6A4, TSHR |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 2.074E-05 | 2.805E-03 | CYP1A1, CYP1B1, FLT3, NFKB1, NOX4, RORC, SLC6A4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.074E-05 | 2.805E-03 | CA12, CA2, CA4, CA7, MMP1, MMP2, MMP9, NR1H4, PPARA, RORC |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.311E-05 | 3.050E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.311E-05 | 3.050E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 2.636E-05 | 3.338E-03 | HTR2A, HTR2B, HTR2C |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 2.636E-05 | 3.338E-03 | HTR2A, HTR2B, HTR2C |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.466E-05 | 4.102E-03 | CYP1A1, CYP1A2 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 3.715E-05 | 4.349E-03 | CYP1A1, LMNA, MMP2, NOX4, PPARA, SLC6A4 |
| BP | Unclassified; | GO:0042310; vasoconstriction | 4.719E-05 | 5.336E-03 | HTR2A, HTR2B, SLC6A4 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 6.373E-05 | 6.904E-03 | AHR, KDR, MAPT |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 6.498E-05 | 7.005E-03 | AHR, NR1H4, PIM1, PPARA, RORC |
| BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 8.669E-05 | 9.076E-03 | AXL, FLT3, IGF1R, KDR, MET |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.487E-10 | 4.254E-08 | CA12, CA2, CA4, CA7, CA14 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 2.010E-07 | 9.802E-06 | FABP4, ADRB3, ADRB1, ADRB2, TSHR |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 2.410E-07 | 9.802E-06 | ADRB3, ADORA3, HTR2B, HTR2C, ADRB1, ADRB2, HTR2A, TSHR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 3.865E-06 | 9.430E-05 | ADRB3, HTR2B, HTR2C, ADRB1, ADRB2, HTR2A |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.950E-06 | 5.946E-05 | CDK1, HTR2B, HTR2C, ADRB1, HTR2A |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 5.694E-06 | 1.116E-04 | HSD17B2, CYP1A1, CYP1B1, IGF1R |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 6.401E-06 | 1.116E-04 | HTR2B, HTR2C, ALOX12, HTR2A, SLC6A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 3.653E-05 | 4.051E-04 | FLT3, MMP1, MMP2, MET, MMP9, NFKB1, IGF1R |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 3.063E-05 | 3.736E-04 | ADRB3, KDR, ADRB1, ADRB2, MET, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.035E-05 | 1.578E-04 | CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 2.069E-05 | 2.805E-04 | FABP4, FABP5, MMP1, PPARA |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 6.562E-05 | 6.158E-04 | PIM1, CYP1B1, MMP9, MET, NFKB1, CDC25B |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 8.225E-05 | 7.167E-04 | HTR2B, HTR2C, ALOX12, HTR2A |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.112E-04 | 8.113E-04 | MMP2, KDR, MMP9, MET, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.013E-04 | 8.113E-04 | ADRB1, ADRB2, PPARA, NFKB1, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 6.307E-05 | 6.158E-04 | FLT3, MMP9, MET, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 6.323E-04 | 3.673E-03 | ADRB3, ADORA3, ADRB1, ADRB2 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 3.256E-04 | 2.091E-03 | FLT3, PIM1, NFKB1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.131E-04 | 8.113E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.218E-04 | 8.254E-04 | MMP1, MMP2, MMP9 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04924 | Renin secretion | 4.583E-04 | 2.796E-03 | ADRB3, ADRB1, ADRB2 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.725E-03 | 7.795E-03 | MMP2, PIM1, NFKB1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 6.741E-04 | 3.738E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.967E-03 | 8.569E-03 | KDR, MET, NFKB1, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 1.582E-03 | 7.424E-03 | CDK1, CDC25B, IGF1R |
| 09150 Organismal Systems | 09154 Digestive system | hsa04970 | Salivary secretion | 1.199E-03 | 6.094E-03 | ADRB3, ADRB1, ADRB2 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 9.457E-04 | 5.017E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.325E-03 | 6.467E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| NA: NA | Cardiogenic shock | NA | ADRB1; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2A; HTR2C; SLC6A4; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | ADRB3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Skin infections | L00-L99 | ADRB2; |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Septic shock | A41.9 | ADRB1; |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADRB1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR2A; HTR2C; SLC6A4; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; |
| NA: NA | Bradycardia | NA | ADRB2; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | SLC6A4; |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | ADRB3; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; MMP2; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADRB1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | SLC6A4; |
| NA: NA | Chronic low back pain | NA | SLC6A4; |
| H00-H59: Diseases of the eye and adnexa | Chronic open-angle glaucoma | H40 | ADRB1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | ADRB3; HTR2C; SLC6A4; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| NA: NA | Appetite suppressant | NA | SLC6A4; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADRB2; ADRB3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; HTR2C; SLC6A4; |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | SLC6A4; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; ADRB1; ADRB2; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ADRB1; CA2; |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR2A; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| I00-I99: Diseases of the circulatory system | Circulatory disorders | I00-I99 | ADRB1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | HTR2A; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| J00-J99: Diseases of the respiratory system | Chronic breathing disorders | J44-J47 | ADRB2; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Premature labour | O60.1, P07.3 | ADRB2; |
| NA: NA | Primary insomnia | NA | HTR2C; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | HTR2C; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | SLC6A4; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; HTR2C; |
| NA: NA | Neurogenic shock | NA | ADRB1; |
| N00-N99: Diseases of the genitourinary system | Neurogenic bladder dysfunction | N31.9 | ADRB2; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | ADRB3; HTR2B; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; ADRB3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRB2; ADRB3; HTR2C; SLC6A4; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | SLC6A4; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | ADRB3; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| NA: NA | Depressive disorders | NA | SLC6A4; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2A; HTR2B; HTR2C; SLC6A4; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| N00-N99: Diseases of the genitourinary system | Vasomotor symptoms | N95.1 | SLC6A4; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| I00-I99: Diseases of the circulatory system | Ventricular fibrillation | I49.01 | ADRB1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ADRB3; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| NA: NA | Exacerbations of acute asthma | NA | ADRB2; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| NA: NA | Menopausal staging | NA | SLC6A4; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A; MAPT; |
| G00-G99: Diseases of the nervous system G00-G99 | Central and peripheral nervous diseases | G96.9 | ADRB1; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
| NA: NA | GIST | NA | FLT3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3; ADRB1; ADRB3; HTR2A; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A; SLC6A4; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADRB1; ADRB3; HTR2A; HTR2C; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
| I00-I99: Diseases of the circulatory system | Maintenance of normal sinus rhythm | I46-I49 | ADRB1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depression | F32, F33 | SLC6A4; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | ADRB1; HTR2A; HTR2B; SLC6A4; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; |
| NA: NA | Heart block | NA | ADRB2; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADRB1; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HTR2B; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| NA: NA | Addiction | NA | HTR2A; |
| I00-I99: Diseases of the circulatory system | Acute supraventricular tachycardia | I47.1 | ADRB1; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C; |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; ADORA3; |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | HTR2B; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADRB1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| NA: NA | HIV infections | NA | AHR; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | ADRB1; CA2; |
| I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Aging skin | L00-L99 | ADRB2; |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | HTR2A; HTR2C; |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | ADRB1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR2C; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HTR2A; HTR2C; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| J00-J99: Diseases of the respiratory system | Acute asthma | J45 | ADRB2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; TYR; |
| NA: NA | Chemotherapyinduced emesis | NA | SLC6A4; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRB1; ADRB2; ADRB3; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| NA: NA | Angina | NA | ADRB1; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | ADRB2; SLC6A4; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | ADRB1; ADRB3; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
| I00-I99: Diseases of the circulatory system | Heart arrhythmia | I47-I49 | ADRB1; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; NFKB1; FLT3; ADORA3; MMP9; SLC6A4; MMP2; CDC25B; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ADRB2; |
| J00-J99: Diseases of the respiratory system | Bronchodilator | J45 | ADRB1; ADRB2; |
| NA: NA | Myalgia | NA | SLC6A4; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| NA: NA | Ventricular premature beats | NA | ADRB1; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADRB2; ADRB3; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; MMP9; MMP2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Smoking cessation | F17.2 | SLC6A4; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
